FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:998-999 September 27, 2001 Number 13 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Packer et al. (May 31 issue)¹ report that the Carvedilol Prospective Randomized Cumulative Survival Study was stopped early on the recommendation of the data and safety monitoring board because of a significant beneficial effect of carvedilol on survival. The patients in the study had a mean ejection fraction of 19.8 percent. The mean duration of follow-up was 10.4 months. At the time that the study was terminated, the mortality rate was 16.8 percent in the placebo group and 11.2 percent in the carvedilol group.

In the Beta-Blocker Evaluation of Survival Trial (BEST), reported in the same issue . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.